Adjuvant therapy for pathologic stage C prostate cancer: a casualty of the PSA revolution?
作者信息
Anscher M S
机构信息
Department of Radiation Oncology, Duke Comprehensive Cancer Center, Duke University Medical Center, Durham, NC, 27710, USA.
出版信息
Int J Radiat Oncol Biol Phys. 1996 Feb 1;34(3):745-7. doi: 10.1016/0360-3016(95)02294-5.
PMID:8621301
Abstract
摘要
相似文献
1
Adjuvant therapy for pathologic stage C prostate cancer: a casualty of the PSA revolution?病理分期为C期前列腺癌的辅助治疗：前列腺特异抗原（PSA）革命的牺牲品？
Int J Radiat Oncol Biol Phys. 1996 Feb 1;34(3):745-7. doi: 10.1016/0360-3016(95)02294-5.
2
[Not Available].
Aktuelle Urol. 2016 Feb;47(1):22-4. doi: 10.1055/s-0041-110295. Epub 2016 Feb 22.
3
Impact of Postoperative Radiotherapy in Men with Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis.根治性前列腺切除术后前列腺特异性抗原持续升高的男性术后放疗对生存的影响：长期生存分析。
Eur Urol. 2017 Dec;72(6):910-917. doi: 10.1016/j.eururo.2017.06.001. Epub 2017 Jun 13.
4
The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.根治性前列腺切除术后前列腺特异性抗原持续存在对预测淋巴结阳性前列腺癌患者临床进展和癌症特异性死亡率的作用。
Eur Urol. 2016 Jun;69(6):1142-8. doi: 10.1016/j.eururo.2015.12.010. Epub 2015 Dec 31.
5
Stage T1-2 prostate cancer with pretreatment prostate-specific antigen level < or = 10 ng/ml: radiation therapy or surgery?前列腺特异性抗原水平≤10 ng/ml的T1-2期前列腺癌：放射治疗还是手术治疗？
Int J Radiat Oncol Biol Phys. 1997 Jul 1;38(4):723-9. doi: 10.1016/s0360-3016(97)00123-5.
6
[Treatment for cancer specifically diagnosed in high-aged population, prostate cancer].[针对高龄人群中明确诊断出的癌症——前列腺癌的治疗]
Nihon Ronen Igakkai Zasshi. 2006 Jan;43(1):71-3. doi: 10.3143/geriatrics.43.71.
7
Evaluation of serum prostate-specific antigen levels after postoperative radiation therapy for pathologic stage T3, N0 prostate cancer.
Mayo Clin Proc. 1996 Mar;71(3):242-8. doi: 10.4065/71.3.242.
8
Positive resection margin and/or pathologic T3 adenocarcinoma of prostate with undetectable postoperative prostate-specific antigen after radical prostatectomy: to irradiate or not?前列腺癌根治术后切缘阳性和/或病理T3期腺癌且术后前列腺特异性抗原检测不到：是否进行放疗？
Int J Radiat Oncol Biol Phys. 2002 Mar 1;52(3):674-80. doi: 10.1016/s0360-3016(01)02677-3.
9
Preoperative serum prostate-specific antigen and Gleason grade as predictors of pathologic stage in clinically organ confined prostate cancer: implications for the choice of primary treatment.术前血清前列腺特异性抗原和Gleason分级作为临床器官局限性前列腺癌病理分期的预测指标：对初始治疗选择的意义
Int J Radiat Oncol Biol Phys. 1994 Sep 30;30(2):317-22. doi: 10.1016/0360-3016(94)90010-8.
10
Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.对于具有不良病理特征的前列腺癌患者，根治性前列腺切除术后辅助放疗可改善生化结局。
Int J Radiat Oncol Biol Phys. 2005 Mar 1;61(3):714-24. doi: 10.1016/j.ijrobp.2004.06.018.
Zotero 插件